
Emmanuelle Remorca Tiongson MD (She/Her)
Neuromuscular Medicine
Clinical Associate Professor of Neurology, Keck Medicine, University of Southern California; Associate Program Director, Child Neurology Residency Program
Join to View Full Profile
4650 W Sunset Blvd# 82Los Angeles, CA 90027
Phone+1 323-361-2471
Fax+1 323-361-1109
Dr. Tiongson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Neuromuscular Medicine (Neurology), 2016 - 2017
Children's Hospital Los AngelesFellowship, Child Neurology, 2013 - 2016
Children's Hospital Los AngelesResidency, Pediatrics, 2011 - 2013
Saint Louis University School of MedicineClass of 2011
Certifications & Licensure
CA State Medical License 2012 - 2026
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine
Publications & Presentations
PubMed
- Effect of the COVID-19 Pandemic on the Quality of Life of Pediatric Patients with Myasthenia.Natasha N Sosa, Marielle Pascual, Yvette Paquin, Adina Dawoud, Jed David
Journal of Child Neurology. 2025-08-26 - 6 citationsEculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.John F Brandsema, Matthew Ginsberg, Hideki Hoshino, Masakazu Mimaki, Satoru Nagata
Pediatric Neurology. 2024-07-01 - 4 citationsSafety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder.Jonathan D Santoro, Saba Jafarpour, Saba Jafarpour, Mellad M Khoshnood, Natalie K Boyd
American Journal of Medical Genetics. Part A. 2024-05-01
Press Mentions
Novartis $2 Million Gene Therapy for Rare Disorder Is World's Most Expensive DrugMay 25th, 2019
$2.1m Novartis Gene Therapy to Become World's Most Expensive DrugMay 25th, 2019
Novartis $2 Million Gene Therapy for Rare Disorder Is World's Most Expensive DrugMay 24th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









